Skip to main content
PMC home page
World Journal of Gastroenterology logoLink to World Journal of Gastroenterology
. 2007 Jan 14;13(2):236–243. doi: 10.3748/wjg.v13.i2.236

Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria

Benoit Foligne 1,2,3, Sophie Nutten 1,2,3, Corinne Grangette 1,2,3, Véronique Dennin 1,2,3, Denise Goudercourt 1,2,3, Sabine Poiret 1,2,3, Joelle Dewulf 1,2,3, Dominique Brassart 1,2,3, Annick Mercenier 1,2,3, Bruno Pot 1,2,3
PMCID: PMC4065951  PMID: 17226902

Abstract

AIM: To investigate the correlation between the in vitro immune profile of probiotic strains and their ability to prevent experimental colitis in mice.

METHODS: in vitro immunomodulation was assessed by measuring interleukin (IL)-12p70, IL-10, tumor necrosis factor alpha (TNFα) and interferon γ (IFNγ) release by human peripheral blood mononuclear cells (PBMCs) after 24 h stimulation with 13 live bacterial strains. A murine model of acute TNBS-colitis was next used to evaluate the prophylactic protective capacity of the same set of strains.

RESULTS: A strain-specific in vivo protection was observed. The strains displaying an in vitro capacity to induce higher levels of the anti-inflammatory cytokine IL-10 and lower levels of the inflammatory cytokine IL-12, offered the best protection in the in vivo colitis model. In contrast, strains leading to a low IL-10/IL-12 cytokine ratio could not significantly attenuate colitis symptoms.

CONCLUSION: These results show that we could predict the in vivo protective capacity of the studied lactic acid bacteria (LAB) based on the cytokine profile we established in vitro. The PBMC-based assay we used may thus serve as a useful primary indicator to narrow down the number of candidate strains to be tested in murine models for their anti-inflammatory potential.

Keywords: Inflammatory bowel disease, Probiotics, Cytokines, Peripheral blood mononuclear cells, Trinitrobenzene sulfonate-induced colitis

INTRODUCTION

Probiotic lactobacilli and bifidobacteria are increasingly recognized as a way to prevent and/or treat intestinal disorders[1]. Probiotic treatment has been successful in a limited number of clinical inflammatory bowel disease (IBD) trials[2,3], as well as in various experimental rodent models for acute and chronic intestinal inflammation[4]. Cytokines are key regulators of inflammation in IBD, and several pro-inflammatory and immune regulatory cytokines are dysregulated in the mucosa of IBD patients. Probiotic–mediated immunomodulation represents an interesting option in the management of IBD[5] and it was shown that both the systemic and mucosal immune systems can be modulated by orally delivered bacteria[6-8]. However, not all candidate probiotics have been proven equally efficient due to the differences in survival and persistence of the strain in the gastro-intestinal tract, and/or to strain-specific interactions of the probiotic with the host immune system[9-11]. The selection of a successful protective strain may therefore rely on the proper screening of a large number of candidate strains for their technological and immunomodulatory performance.

However, it remains challenging to set up in vitro tests with a fair predictive value that would allow us to narrow down the number of candidate strains to be tested in animal models. Until now, results of in vitro studies have rarely been linked to in vivo effects[12,13]. This could possibly be explained by the variety of parameters that may interfere in the systematic comparison of strains such as the bacterial preparations used (viability, growth phase, dose and timing of administration), possible time effects (early versus late immune responses), or physiological status and type of eukaryotic cells used. When testing human peripheral blood mononuclear cells (PBMCs), the in vitro experiment may also be influenced by the method of PBMC preparation as well as the variable responsiveness of the donors[10,14,15]. Once identified, however, these parameters/factors can be controlled by using standardized methodologies[16], allowing, on the one hand, to classify strains according to the in vitro differences in their interaction with human immunocompetent cells and, on the other hand, to confirm in vivo the “protective capacity” of the best candidate strains (showing between 30% and 70% reduction of the inflammatory score)[16,17]. In this paper we addressed the question whether prophylaxis by oral consumption of live non-pathogenic lactic acid bacteria (LAB) in experimental colitis actually matches their in vitro stimulation profile on human PBMCs. Cytokine profiles released in vitro by human PBMC stimulated with 13 bacterial strains were compared with the protection they offered in a murine trinitrobenzene sulfonate (TNBS) model of acute colitis. The results of this study demonstrate that the in vitro immune profiling of the strains is indeed predictive of their in vivo protective effect in a mouse colitis model. These findings support the idea that promising LAB strains for IBD alleviation may be discriminated from non-protective ones using in vitro and in vivo assays.

MATERIALS AND METHODS

Bacterial strains and growth conditions

Bacterial strains and their origin are shown in Table 1. Lactobacillus strains were grown under limited aeration at 37°C in MRS medium (Difco) and Bifidobacterium strains were grown anaerobically in MRS supplemented with 0.05% L-cysteine-hydrochloride (Sigma). Lactococcus lactis MG1363 was grown at 30°C in M17 medium supplemented with 0.5% glucose. E. coli and S. gordonii were grown at 37°C in LB and BHI medium (Difco), respectively. The number of live bacteria (CFU) was deduced from the absorbance at 600 nm (A600), using a calibration curve for each strain. For immune cell stimulation, bacterial cells were grown till stationary phase, washed and resuspended at 1 × 109 CFU/mL in phosphate buffered saline (PBS) containing 20% glycerol and stored at -80°C until used for assays. For in vivo experiments, bacteria were grown for 18 h, washed twice in sterile PBS (pH 7.2) and resuspended at 1 × 109 CFU/mL in 0.2 mol/L NaHCO3 buffer (pH 8.8) containing 2% glucose.

Table 1.

Strains used with their origin

Bacterial species /subspecies Strain designation Type of isolate, source and/or reference
Lactobacillus salivarius subsp salivarius Ls33 Commercial strain
Lactobacillus rhamnosus Lr32 Commercial strain
Lactobacillus casei Bl23 ATCC1 393, plasmid-cured
Lactobacillus acidophilus NCFM Human, commercial strain
Lactobacillus acidophilus IPL3 908 Commercial isolate
Lactobacillus plantarum NCIMB 8826 Human, NCIMB2 collection
Lactobacillus plantarum Lp115 Commercial strain
Bifidobacterium animalis subsp lactis BL04 Commercial strain
Bifidobacterium animalis subsp lactis BI07 Commercial strain
Bifidobacterium bifidum BB02 Commercial strain
Lactococcus lactis MG1363 Cheese starter derivative[42]
Streptococcus gordonii V288 (Challis) ATCC1 35105
Escherichia coli (non-pathogenic) TG1 Cloning strain[43]
Open in a new tab
1

ATCC: American type culture collection, Manassas, (VA), USA;

2

NCIMB: National collection of industrial and marine bacteria, Terry Research Station, Aberdeen, Scotland;

3

Institut Pasteur Lille, Lille, France.

PBMC isolation

PBMCs were isolated from peripheral blood of healthy donors as previously described[18]. Briefly, after a Ficoll gradient centrifugation (Pharmacia, Uppsala, Sweden), mononuclear cells were collected, washed in RPMI 1640 medium (Live technologies, Paisley, Scotland) and adjusted to 2 × 106 cells/mL in RPMI 1640 supplemented with gentamicin (150 μg/mL), L-glutamine (2 mmol/L), and 10% foetal calf serum (FCS) (Gibco-BRL).

Induction of cytokine release

PBMCs (2 × 106 cells/mL) were seeded in 24-well tissue culture plates (Corning, NY). Twenty microliters of a thawed bacterial suspension at 109 CFU/mL were added (bacteria:cell ratio of 10:1). PBS containing 20% glycerol was used as a negative (non-stimulated) control. On the basis of preliminary time-course studies, 24 h stimulation corresponded to the best time point for cytokine responses of bacteria stimulated-PBMCs. After 24 h stimulation at 37°C in an atmosphere of air with 5% CO2, culture supernatants were collected, clarified by centrifugation and stored at -20°C until cytokine analysis. Neither medium acidification nor bacterial proliferation was observed. Cytokines were measured by ELISA using BD pharmingen antibody pairs (BD Biosciences, San Jose, Ca, USA) for tumor necrosis factor alpha (TNFα), interleukin (IL)-10, interferon γ (IFNγ) and IL-12p70, according to the manufacturer’s recommendations.

Induction of colitis and inflammation scoring

Animal experiments were performed in an accredited establishment (number 59-35009; Institut Pasteur de Lille, France) and approved guidelines, according to French Ethical Committee and European Union Normatives (number 86/609/CEE). BALB/c and C57/Bl6 mice (female, 8 wk) were obtained from Charles River (St Germain sur l’Arbresle, France). A standardized murine TNBS colitis model was used in which sublethal levels of inflammation were induced[16]. Briefly, a 50 μL solution of 100 mg/kg (BALB/c mice) or 180 mg/kg (C57Bl6 mice) TNBS (Sigma) in 50% ethanol was slowly administered in the colon via a 3.5 F catheter. Bacterial suspensions (100 µL), containing 1 × 109 CFU/mL in NaHCO3 buffer (or buffer alone for controls) were administered intragastrically to mice each day, starting 5 d before until d 1 after TNBS administration. The mice were weighed and killed 48 h after TNBS administration. Colons were removed, washed and opened. Inflammation grading was performed by two blinded observers, using the Wallace scoring method[19]. Results are expressed as % protection, corresponding to the reduction of the mean macroscopic inflammation score of bacteria-treated mice (n = 10) in comparison to the mean score of TNBS-treated control mice (NaHCO3 buffer-treated mice, n = 10)[16]. Histological analysis was performed on hematoxylin/eosin-stained 5 μm tissue sections from colon samples fixed in 10% formalin and embedded in paraffin.

Statistical analysis

Results were analyzed by the non-parametric one-way analysis of variance and Mann-Whitney U test. Differences were judged to be statistically significant when the P value was < 0.05. For in vivo experiments, only protection levels exceeding 30% (positive and negative) were considered to be relevant, as previously described[16]. For the calculation of the IL-10/IL-12 ratio, all undetectable IL-12 values (below 50 pg/mL) were arbitrarily set at 50 pg/mL level to normalize aberrant quotients. Association of variables was analyzed by the P value-assigned Spearman rank correlation coefficient.

RESULTS

Cytokine release by PBMCs is strain specific

The in vitro immunostimulation by 13 live bacterial strains (Table 1) of PBMCs collected from 6 to 12 independent donors, revealed distinct and typical patterns of cytokine release. TNFα release was quite uniform for the different LAB investigated, while IFNγ showed variations tending to parallel IL-12 profiles (data not shown). IL-10 and IL-12 levels displayed a strain-specific pattern (Figure 1A and B). Variations in IL-10 concentrations were substantial with values ranging between 200 and 3000 pg/mL depending on the bacterial strain. For IL-12, we also observed significant variations between strains, covering a range of cytokine levels of 50 to 1200 pg/mL. As IL-10 and IL-12 appeared to be the most discriminative cytokines, we used the IL-10/IL-12 ratio (Figure 1C) to distinguish between strains exhibiting a ”pro-“ versus “anti-inflammatory” profile (low versus high IL-10/IL-12 ratio, respectively). This approach was found to be useful to identify strains with marked opposite profiles, but did not allow discrimination of strains with median cytokine ratios.

Figure 1.

Figure 1

Open in a new tab

Strain-specific patterns of IL-10 (A) and IL-12p70 (B) release for various bacterial strains and IL-10/IL-12 ratios (C) for 6 to 12 independent healthy donors. Bars represent the mean ± SE values in pg/mL for 6 to 12 independent healthy donors. Ranked box and whisker plots show the median values and first to third quartiles in boxes. Different letters indicate significant differences according to Mann-Whitney U test (P < 0.05).

The variation in absolute cytokine concentrations released by PBMCs derived from different donors was examined by conducting successive experiments with a limited set of 6 strains (E. coli TG1, L. salivarius Ls33, L. casei Bl23, L. plantarum NCIMB 8826, Lc. lactis MG1363 and L. acidophilus NCFM). In general, for a variety of individual donors, the ranking of strains was quite reproducible: the most potent “anti-inflammatory” strains induced the highest IL-10 responses in all donors, while other strains were stronger IL-12 inducers in most donors. As an example, Figure 2A and B shows the IL-10 and IL-12 expression profiles for four donors in response to the six “reference” strains used. Relative differences between two strains, expressed as a percentage of the highest inducer, taken as internal control, were quite constant for all donors (Figures 2C and D). For example, we consistently found 35% and 82% difference (P < 0.05) between the strains L. salivarius Ls33 and L. acidophilus NCFM, for IL-10 and IL-12 induction, respectively. Based on these observations, both strains could be compared in a semi-quantitative way, using their average IL-10 and IL-12 release patterns upon stimulation of PBMCs from four different donors. To that extent we calculated a full matrix of P-values for the IL-10/IL-12 ratios obtained from several overlapping studies with reference strains as well as new isolates, for at least 4 PBMC donors, which allowed us to rank strains from an “anti-inflammatory” to a “pro-inflammatory” profile.

Figure 2.

Figure 2

Open in a new tab

IL-10 (A) and IL-12p70 (B) release in 4 distinct individual human PBMC donors and the expression level of IL-10 (C) and IL-12p70 (D). Individual values are represented in pg/mL while IL-10 and IL-12p70 levels are expressed as % of the highest inducer strain. aP < 0.05.

When applied to the 13 strains used in this study, this methodology established a semi-quantitative ranking, which could classify strains L. salivarius Ls33, L. casei Bl23, L. rhamnosus Lr32, L. acidophilus IPL908 as more anti-inflammatory than the three bifidobacteria and the two L. plantarum strains. Lc. lactis MG1363, S. gordonii V288 and L. acidophilus NCFM® strains showed a slightly pro-inflammatory profile with a very low IL-10/IL-12 ratio.

Protection of TNBS-induced colitis was strain-specific

We investigated the protective effect of the 13 strains studied in vitro against TNBS-induced colitis in mice (Figure 3). Ls33, Lr32, Bl23, IPL908 and BL04 strains consistently led to a considerable attenuation of colitis (data represent the result of usually 2 to 4 distinct experiments), with reduced weight loss, improved clinical parameters (rectal bleeding, stool consistency, i.e. liquid pasty stool and diarrhoea, lethargy; data not shown) and reduced macroscopic inflammation scores. Considering the % protection as the reduction of the mean macroscopic inflammation score of bacteria-treated mice (n = 10) in comparison to the mean score of TNBS-treated control mice, the Lactobacillus plantarum strains and the BB02 and Bl07 bifiidobacterial strains induced moderate but significant levels of protection. In contrast, no improvement in colitis was observed for the strains L. acidophilus NCFM, Lc. lactis MG1363 or S. gordonii V288 and for the non-pathogenic E. coli TG1. None of these strains, however, aggravated the symptoms of colitis. Histological analysis corroborated these findings, showing dramatic improvement in epithelial lesions of the animals receiving protective strains, with a significant decrease in goblet cells and crypt loss (data not shown), and reduced inflammatory infiltrates (mainly neutrophils) accompanied with a reduction of the colon wall thickness to almost normal levels (Figure 4).

Figure 3.

Figure 3

Open in a new tab

Protective effect of LAB strains against TNBS-induced colitis in BALB/c mice. Results are expressed as a % reduction of the mean macroscopic inflammation of mice treated with LAB as compared to the mean score of non-treated mice. Colitis index was assessed 48 h after TNBS administration. Each bar represents an independent experiment and corresponds to the ratio of control and LAB-treated mice groups (n = 10). aP < 0.05, bP < 0.01 vs TNBS-control group. The horizontal dashed lines indicate the 30% threshold of the uncertain statistical significance.

Figure 4.

Figure 4

Open in a new tab

Hematoxylin/eosin staining of representative cross-sections of murine (BALB/c) distal colon (HE, x 20). A: Normal appearance of the colon from a negative control mice; B: Thickening of the colon wall accompanied with massive inflammatory infiltrate and muscular necrosis 2 d after TNBS-induction of colitis; C: Reduction of histological damage in L. salivarius Ls33-treated mice after TNBS administration; D: Lack of histological improvement of colitis in L. acidophilus NCFM-treated mice after TNBS administration.

Additional experiments confirmed this strain-specific protection in mice with a different genetic background (C57/Bl6 mice). The protection observed in BALB/c mice with L. salivarius Ls33 (56.5% ± 7.2%, P < 0.01) was confirmed in C57/Bl6 mice (47%, P < 0.01), whereas the L. acidophilus NCFM® and E. coli strains alleviated colitis neither in BALB/c mice (-12.5% ± 2.7%, NS; and +19.4% ± 3.7%, NS, respectively) nor in C57/Bl6 (+26%, NS; and -6.4%, NS, respectively).

In vivo / In vitro correlation

Considering both in vitro and in vivo results, it was evident that strains displaying the highest in vitro anti-inflammatory profile (a high IL-10/IL-12 ratio) were the most protective in the in vivo colitis model, while those leading to intermediary in vitro IL-10/IL-12 ratios showed limited protection. In contrast, bacteria characterized by a low anti-inflammatory potential (low IL-10/IL-12 ratio) did not improve inflammation at all. As a result, with the exception of the Gram-negative E. coli, the ranking of all Gram-positive bacteria investigated, based on the in vitro cytokine profiling, closely matched the ranking based on the improvement of colitis symptoms. Although this link could not be expressed as an “exact linear” association between % protection and IL-10/IL-12 ratio, it was found to be highly significant using the Spearman rank correlation coefficient (rs = 0.825, P <0.001) (Figure 5).

Figure 5.

Figure 5

Open in a new tab

Correlation between the average protection against experimental colitis and the mean IL-10/IL-12 ratios obtained in vitro, for all investigated strains. Spearman coefficient (rs = 0.825, P < 0.001). The horizontal dashed lines indicate the 30% threshold of unprotectiveness.

DISCUSSION

Immunomodulation through probiotics represents one of the current treatment options for IBD[5,20] and specific strains may stimulate immunomodulatory mediators, inhibit pro-inflammatory cytokines and influence the phenotypes of immunocompetent cells with subsequent events such as migration of dendritic cells and induction of regulatory T cells[15,21]. The mechanisms of action of probiotics are most probably multi-factorial, involving a variety of effector signals, cell types and receptors[22], and strains may differ in their respective ability to trigger these signals considering both immunocompetent and intestinal epithelial cells[23]. It has been proposed that some probiotics are able to prevent or restore intestinal homeostasis after an immune dysregulation, improving mucosal barrier functions as well as down-regulating inflammatory responses[24,25].

In this study, we aimed at developing a simple and standardized in vitro test allowing preliminary classification of candidate probiotic strains according to their immune modulation capacity that would be predictive of their in vivo effect. To this end, we ranked 13 LAB strains with reference to the IL10/IL12 cytokine ratio induced on human PBMCs and further assessed their protective effect against TNBS-induced colitis in mice.

We observed strong strain-specific variations of the in vitro cytokine induction profiles after stimulation of immunocompetent cells, which confirms the results reported in previous studies[9-11,15,26]. We also noted that differences between blood donors did not prevent us ranking the strains based on their cytokine responses as the relative responses of PBMCs to various LAB were consistent from one donor to another. PBMCs from healthy donors can thus be used to screen the immunomodulatory activity of candidate probiotic strains and this test/assay appears to be a good indicator of in vivo anti-inflammatory strains. Despite the fact that this assay does not clarify the physiological mechanism(s) involved, it seems to mimic how the immune system may sense the bacterial strains and consequently polarise the immune response. Strains leading to a high IL-10/IL-12 ratio would more easily slow down an early Th1 response.

In accordance with this hypothesis, we found differences in the in vivo protective capacity of the 13 studied strains against TNBS-induced inflammation[27]. This strain-specificity has already been described in other experimental models of colitis[28-31]. The variations we observed between different LAB strains in this respect cannot simply be explained by differences in persistence, especially when daily administrations maintain the level of bacteria in the gastro-intestinal tract. Of note, we have previously verified whether the anti-inflammatory profiles could in any way be linked to in vitro properties such as gastric juice (pepsin/pancreatin) and bile salt resistance, epithelial cell adhesion and in vivo intestinal persistence (unpublished data). However, no link was found between them.

Above all, we have demonstrated in this study that the ranking of strains obtained on the basis of an in vitro IL-10/IL-12 cytokine induction ratio closely matches the ranking of the in vivo ability of the strains to attenuate experimental colitis. The concordance between the in vitro and in vivo assays has been illustrated in the case of a cell-wall mutant of L. plantarum[18]. The importance of the IL-10/IL-12 ratio has also recently been highlighted by Peran et al[32] who showed that administration of a specific strain of Lactobacillus salivarius subsp. salivarius could improve the recovery of inflamed tissue in a TNBS model of rat colitis. This strain was selected among 30 LAB strains for eliciting the best IL-10/IL-12 and IL-10/TNFα ratios. Unfortunately, no strains exhibiting a moderate or low IL-10/IL-12 profile were included in the in vivo study, which could have validated the proposed screening strategy. Similarly, in vitro tests on immunocompetent cells have been used successfully to study the effect of distinct bacterial fractions (intact cell walls, protoplast and polysaccharide-peptidoglycans) of the strain Lactobacillus casei Shirota[33]. Using the ability of this strain to inhibit the LPS-induced IL-6 in mice bone marrow derived-DCs and PBMCs isolated from ulcerative colitis patients, the authors could establish that the polysaccharide-peptidoglycan complex was the most efficient compound to improve chronic colitis and ileitis in their mice model. Another example attesting similar links between in vitro macrophage stimulation and related protection in a murine TNBS model of colitis was reported for the anti-inflammatory drug “catapolside”[34], leading to clinical trials in IBD patients in Korea.

Recently, the PBMC IL-10/IL-12 ratio has also been used to follow the immunomodulatory properties of probiotics in a clinical study on irritable bowel syndrome (IBS)[31]. Despite different aetiology and characteristics, IBD and IBS share some aspects of immune dysregulation, and IBS has been documented to be associated with low-grade inflammation. Concomitantly to alleviation of the main IBS symptoms, the authors showed normalization of the PBMC IL-10/IL-12 ratio in patients receiving probiotics versus placebo, showing that in vivo probiotic efficiency can be correlated to specific in vitro assays.

Despite the positive correlation observed between in vivo protection and in vitro cytokine ratio, some restrictions are clear. First of all, the link is not valid for Gram-negative bacteria. Gram-negative bacteria, including both non-pathogenic and pathogenic strains, are well known to be potent inducers of monocytic IL-10, while Gram-positive species preferentially stimulate IL-12 [10]. These observations do not exclude Gram-negative strains from being anti-inflammatory. For example, bacteria such as the E. coli strain Nissle[35] or virulence-attenuated Yersinia pseudotuberculosis mutants[36] have been shown to be able to reduce colonic lesions and inflammatory mediators in murine models of experimental colitis. Secondly, it is not excluded that Lactobacillus strains may moderate colitis by non immune-related modes of action, as for example by acting on barrier integrity or influencing the oxidative pathway[37]. Alternatively, LAB strains with a rather pro-inflammatory profile may have other health benefits which substantiate their probiotic status[38,39].

The methods described in this paper can be used to screen a larger set of potential probiotic strains for their immunomodulatory properties, since they are relatively simple and quite reproducible. We are currently building a reference database including both in vitro cytokine profiles, as well as protection levels measured in the TNBS mice model for selected reference strains. This database encompasses strains and blends used in former clinical trials in IBD (i.e. L. rhamnosus GG, VSL#3 and E. coli strain Nissle[2,3,40,41]), which could further support and validate the predictive value of the screening strategy presented in this paper.

In conclusion, our results linked in vitro and in vivo anti-inflammatory properties of a series of LAB and confirm that potential probiotic strains can be pre-screened in vitro for their immunomodulating potential, before animal and clinical investigations. This allows pre-selection of probiotics able to modulate the host immune system in a specific way while reducing considerably the use of animals for screening purposes. Besides these ethical considerations, the comparative study of strains carefully selected for either pro- or anti-inflammatory properties will assist further investigation of the mechanism(s) by which specific probiotics signal to the host.

COMMENTS

Background

Evidence exists for the protective role of selected probiotic strains in inflammatory bowel disease. Probiotic strains have clearly been shown to differ in their in vitro interaction with immunocompetent cells, especially in terms of cytokine responses. No clear link has been established so far between the in vitro immunomodulation potential (e.g. on PBMC’s) of the probiotic strain and its ability to prevent experimental colitis in mice (e.g. in TNBS- induced colitis). The use of simple in vitro methods to select the most efficient strains for possible clinical trials will improve the quality and reduce the costs of this type of research.

Research frontiers

Improving gastrointestinal function is important for IBD patients and fundamental research is needed to develop new treatments for such pathogenesis. Probiotics are generally accepted to be one of these alternative methods. Few original research papers, however, have evaluated the potential of this approach by focusing on the level of the bacterial strain or strains used.

Probiotic-mediated immunomodulation represents an interesting option in the management of IBD and there is evidence that the immune system can be modulated by orally delivered bacteria. However, in some animal and clinical studies, probiotics did not show the expected beneficial effect. The selection of a successful protective strain may rely on a proper screening of a large number of candidate strains for their technological and immunomodulatory performance, as recently published in WJG. Together with proper in vitro analytical methods, the use of a reliable animal model is therefore indispensable. Using a well-standardized animal model, we have demonstrated that consistent differences in anti-inflammatory potential of several orally administered lactic acid bacteria could be observed in TNBS-induced colitis.

In the present study we linked for the first time the results of in vitro and in vivo anti-inflammatory readouts for 13 selected LAB, and confirmed herewith the strain-specific nature of the potential of probiotics to modulate the host's immune system and in assisting in the alleviation of intestinal disorders, IBD in particular.

Innovations and breakthroughs

Linking in vitro and in vivo anti-inflammatory properties of a series of LAB can confirm the interest of screening potential probiotic strains using in vitro assays, before launching animal and clinical investigations. This allows not only the pre-selection of probiotics able to modulate the host’s immune system in a specific way while reducing considerably the use of animals for screening purposes, but also results in a classification of microorganisms that could be useful for the study or comparison of other probiotic properties. So, besides ethical considerations, the comparative study of strains carefully selected for either pro- or anti-inflammatory properties will assist further investigation of the mechanism(s) by which specific probiotics signal to the host.

Applications

The use of probiotic strains in IBD treatment has been controversial, because of some major drawbacks. The first is the type of inflammatory disease targeted (Crohn’s disease on the one hand, with low success levels, versus ulcerative colitis and pouchitis where treatment was more successful). The second is that a comparison between a therapeutic preventive application in combination with or without traditional medication, is not always clear. The third is that the choice of strains or the mixture thereof is often made rather artificially and driven by available commercial preparations which are not necessarily developed or suitable for this type of medical application. Using the described selection procedure, the influence of well-selected strains (e.g. with expected positive and negative performance as anti-inflammatory agent) in different conditions (with or without traditional medication) of a selected animal model (prophylactic or therapeutic) can be evaluated unequivocally. The results should not only allow to select the best possible conditions for the follow-up clinical study but will also help to understand the underlying mechanisms and factors that influence the efficiency of the application.

Terminology

The TNBS mouse model of colitis is a hapten-induced experimental model (TNBS = 2, 4, 6-trinitrobenzene sulfonic acid), which has proven to be a very useful model for studying certain forms of human inflammatory bowel disease. This model has e.g. been used to show that an IL-12-driven, Th1 T cell-mediated inflammation of the colon is not only prevented by systemic administration of anti-IL-12 antibody, but can also be treated this way. Consequently anti-IL-12 is currently used in the treatment of Crohn’s disease. Other studies with this model have established that mucosal inflammation and/or its prevention depend partially on a balance between pro-inflammatory Th1 T cell responses and anti-inflammatory TGF-β and IL-10 responses.

Peer review

This is an interesting study showing that in vitro assays using human PBMCs can partially translate to murine models of colitis giving an indication of the level of expected protection of this particular model of colitis using IL-10/IL-12 ratios. It would be interesting to discover whether this held out if colitis was induced before administration of the probiotic (perhaps a more physiological approach for therapy). However, this does offer some insight into prophylactic approaches for managing patients in remission.

Footnotes

Supported by the EU granted QLK1-2000-00146 DEPROHEALTH research program, Institut Pasteur de Lille funding and funds from DANISCO Franc

S- Editor Liu Y L- Editor Wang XL E- Editor Bai SH

References

  • 1.Bergonzelli GE, Blum S, Brussow H, Corthésy-Theulaz I. Probiotics as a treatment strategy for gastrointestinal diseases? Digestion. 2005;72:57–68. doi: 10.1159/000087638. [DOI] [PubMed] [Google Scholar]
  • 2.Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, Kamm MA, Weismueller J, Beglinger C, Stolte M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617–1623. doi: 10.1136/gut.2003.037747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003;124:1202–1209. doi: 10.1016/s0016-5085(03)00171-9. [DOI] [PubMed] [Google Scholar]
  • 4.Mahida YR, Rolfe VE. Host-bacterial interactions in inflammatory bowel disease. Clin Sci (Lond) 2004;107:331–341. doi: 10.1042/CS20040136. [DOI] [PubMed] [Google Scholar]
  • 5.Hart AL, Stagg AJ, Kamm MA. Use of probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2003;36:111–119. doi: 10.1097/00004836-200302000-00005. [DOI] [PubMed] [Google Scholar]
  • 6.Chapat L, Chemin K, Dubois B, Bourdet-Sicard R, Kaiserlian D. Lactobacillus casei reduces CD8+ T cell-mediated skin inflammation. Eur J Immunol. 2004;34:2520–2528. doi: 10.1002/eji.200425139. [DOI] [PubMed] [Google Scholar]
  • 7.Maassen CB, van Holten-Neelen C, Balk F, den Bak-Glashouwer MJ, Leer RJ, Laman JD, Boersma WJ, Claassen E. Strain-dependent induction of cytokine profiles in the gut by orally administered Lactobacillus strains. Vaccine. 2000;18:2613–2623. doi: 10.1016/s0264-410x(99)00378-3. [DOI] [PubMed] [Google Scholar]
  • 8.McCarthy J, O'Mahony L, O'Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, Fitzgibbon J, O'Sullivan GC, Kiely B, Collins JK, et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut. 2003;52:975–980. doi: 10.1136/gut.52.7.975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Fujiwara D, Inoue S, Wakabayashi H, Fujii T. The anti-allergic effects of lactic acid bacteria are strain dependent and mediated by effects on both Th1/Th2 cytokine expression and balance. Int Arch Allergy Immunol. 2004;135:205–215. doi: 10.1159/000081305. [DOI] [PubMed] [Google Scholar]
  • 10.Hessle C, Andersson B, Wold AE. Gram-positive bacteria are potent inducers of monocytic interleukin-12 (IL-12) while gram-negative bacteria preferentially stimulate IL-10 production. Infect Immun. 2000;68:3581–3586. doi: 10.1128/iai.68.6.3581-3586.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Kimoto H, Mizumachi K, Okamoto T, Kurisaki J. New Lactococcus strain with immunomodulatory activity: enhancement of Th1-type immune response. Microbiol Immunol. 2004;48:75–82. doi: 10.1111/j.1348-0421.2004.tb03490.x. [DOI] [PubMed] [Google Scholar]
  • 12.O'Mahony L, O'Callaghan L, McCarthy J, Shilling D, Scully P, Sibartie S, Kavanagh E, Kirwan WO, Redmond HP, Collins JK, et al. Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans. Am J Physiol Gastrointest Liver Physiol. 2006;290:G839–G845. doi: 10.1152/ajpgi.00112.2005. [DOI] [PubMed] [Google Scholar]
  • 13.Peña JA, Rogers AB, Ge Z, Ng V, Li SY, Fox JG, Versalovic J. Probiotic Lactobacillus spp. diminish Helicobacter hepaticus-induced inflammatory bowel disease in interleukin-10-deficient mice. Infect Immun. 2005;73:912–920. doi: 10.1128/IAI.73.2.912-920.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Christensen HR, Frøkiaer H, Pestka JJ. Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol. 2002;168:171–178. doi: 10.4049/jimmunol.168.1.171. [DOI] [PubMed] [Google Scholar]
  • 15.Hart AL, Lammers K, Brigidi P, Vitali B, Rizzello F, Gionchetti P, Campieri M, Kamm MA, Knight SC, Stagg AJ. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut. 2004;53:1602–1609. doi: 10.1136/gut.2003.037325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Foligné B, Nutten S, Steidler L, Dennin V, Goudercourt D, Mercenier A, Pot B. Recommendations for improved use of the murine TNBS-induced colitis model in evaluating anti-inflammatory properties of lactic acid bacteria: technical and microbiological aspects. Dig Dis Sci. 2006;51:390–400. doi: 10.1007/s10620-006-3143-x. [DOI] [PubMed] [Google Scholar]
  • 17.Foligné B, Grangette C, Pot B. Probiotics in IBD: mucosal and systemic routes of administration may promote similar effects. Gut. 2005;54:727–728. [PMC free article] [PubMed] [Google Scholar]
  • 18.Grangette C, Nutten S, Palumbo E, Morath S, Hermann C, Dewulf J, Pot B, Hartung T, Hols P, Mercenier A. Enhanced antiinflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids. Proc Natl Acad Sci USA. 2005;102:10321–10326. doi: 10.1073/pnas.0504084102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Wallace JL, MacNaughton WK, Morris GP, Beck PL. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology. 1989;96:29–36. doi: 10.1016/0016-5085(89)90760-9. [DOI] [PubMed] [Google Scholar]
  • 20.Fedorak RN, Madsen KL. Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:286–299. doi: 10.1097/00054725-200405000-00018. [DOI] [PubMed] [Google Scholar]
  • 21.Braat H, van den Brande J, van Tol E, Hommes D, Peppelenbosch M, van Deventer S. Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function. Am J Clin Nutr. 2004;80:1618–1625. doi: 10.1093/ajcn/80.6.1618. [DOI] [PubMed] [Google Scholar]
  • 22.Servin AL. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev. 2004;28:405–440. doi: 10.1016/j.femsre.2004.01.003. [DOI] [PubMed] [Google Scholar]
  • 23.Riedel CU, Foata F, Philippe D, Adolfsson O, Eikmanns BJ, Blum S. Anti-inflammatory effects of bifidobacteria by inhibition of LPS-induced NF-kappaB activation. World J Gastroenterol. 2006;12:3729–3735. doi: 10.3748/wjg.v12.i23.3729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Llopis M, Antolín M, Guarner F, Salas A, Malagelada JR. Mucosal colonisation with Lactobacillus casei mitigates barrier injury induced by exposure to trinitronbenzene sulphonic acid. Gut. 2005;54:955–959. doi: 10.1136/gut.2004.056101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Oshima T, Laroux FS, Coe LL, Morise Z, Kawachi S, Bauer P, Grisham MB, Specian RD, Carter P, Jennings S, et al. Interferon-gamma and interleukin-10 reciprocally regulate endothelial junction integrity and barrier function. Microvasc Res. 2001;61:130–143. doi: 10.1006/mvre.2000.2288. [DOI] [PubMed] [Google Scholar]
  • 26.He F, Morita H, Ouwehand AC, Hosoda M, Hiramatsu M, Kurisaki J, Isolauri E, Benno Y, Salminen S. Stimulation of the secretion of pro-inflammatory cytokines by Bifidobacterium strains. Microbiol Immunol. 2002;46:781–785. doi: 10.1111/j.1348-0421.2002.tb02765.x. [DOI] [PubMed] [Google Scholar]
  • 27.Sheil B, McCarthy J, O'Mahony L, Bennett MW, Ryan P, Fitzgibbon JJ, Kiely B, Collins JK, Shanahan F. Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut. 2004;53:694–700. doi: 10.1136/gut.2003.027789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Cross ML, Gill HS. Can immunoregulatory lactic acid bacteria be used as dietary supplements to limit allergies? Int Arch Allergy Immunol. 2001;125:112–119. doi: 10.1159/000053804. [DOI] [PubMed] [Google Scholar]
  • 29.Osman N, Adawi D, Ahrne S, Jeppsson B, Molin G. Modulation of the effect of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of Lactobacillus and Bifidobacterium. Dig Dis Sci. 2004;49:320–327. doi: 10.1023/b:ddas.0000017459.59088.43. [DOI] [PubMed] [Google Scholar]
  • 30.Shibolet O, Karmeli F, Eliakim R, Swennen E, Brigidi P, Gionchetti P, Campieri M, Morgenstern S, Rachmilewitz D. Variable response to probiotics in two models of experimental colitis in rats. Inflamm Bowel Dis. 2002;8:399–406. doi: 10.1097/00054725-200211000-00004. [DOI] [PubMed] [Google Scholar]
  • 31.O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541–551. doi: 10.1053/j.gastro.2004.11.050. [DOI] [PubMed] [Google Scholar]
  • 32.Peran L, Camuesco D, Comalada M, Nieto A, Concha A, Diaz-Ropero MP, Olivares M, Xaus J, Zarzuelo A, Galvez J. Preventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in the TNBS model of rat colitis. World J Gastroenterol. 2005;11:5185–5192. doi: 10.3748/wjg.v11.i33.5185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Matsumoto S, Hara T, Hori T, Mitsuyama K, Nagaoka M, Tomiyasu N, Suzuki A, Sata M. Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clin Exp Immunol. 2005;140:417–426. doi: 10.1111/j.1365-2249.2005.02790.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Kim SW, Choi SC, Choi EY, Kim KS, Oh JM, Lee HJ, Oh HM, Kim S, Oh BS, Kimm KC, et al. Catalposide, a compound isolated from catalpa ovata, attenuates induction of intestinal epithelial proinflammatory gene expression and reduces the severity of trinitrobenzene sulfonic Acid-induced colitis in mice. Inflamm Bowel Dis. 2004;10:564–572. doi: 10.1097/00054725-200409000-00010. [DOI] [PubMed] [Google Scholar]
  • 35.Schultz M, Strauch UG, Linde HJ, Watzl S, Obermeier F, Göttl C, Dunger N, Grunwald N, Schölmerich J, Rath HC. Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. Clin Diagn Lab Immunol. 2004;11:372–378. doi: 10.1128/CDLI.11.2.372-378.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Marceau M, Dubuquoy L, Caucheteux-Rousseaux C, Foligne B, Desreumaux P, Simonet M. Yersinia pseudotuberculosis anti-inflammatory components reduce trinitrobenzene sulfonic acid-induced colitis in the mouse. Infect Immun. 2004;72:2438–2441. doi: 10.1128/IAI.72.4.2438-2441.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Lamine F, Eutamène H, Fioramonti J, Buéno L, Théodorou V. Colonic responses to Lactobacillus farciminis treatment in trinitrobenzene sulphonic acid-induced colitis in rats. Scand J Gastroenterol. 2004;39:1250–1258. doi: 10.1080/00365520410007953. [DOI] [PubMed] [Google Scholar]
  • 38.Varcoe JJ, Krejcarek G, Busta F, Brady L. Prophylactic feeding of Lactobacillus acidophilus NCFM to mice attenuates overt colonic hyperplasia. J Food Prot. 2003;66:457–465. doi: 10.4315/0362-028x-66.3.457. [DOI] [PubMed] [Google Scholar]
  • 39.Sanders ME, Klaenhammer TR. Invited review: the scientific basis of Lactobacillus acidophilus NCFM functionality as a probiotic. J Dairy Sci. 2001;84:319–331. doi: 10.3168/jds.S0022-0302(01)74481-5. [DOI] [PubMed] [Google Scholar]
  • 40.Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108–114. doi: 10.1136/gut.53.1.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut. 2002;51:405–409. doi: 10.1136/gut.51.3.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Gasson MJ. Plasmid complements of Streptococcus lactis NCDO 712 and other lactic streptococci after protoplast-induced curing. J Bacteriol. 1983;154:1–9. doi: 10.1128/jb.154.1.1-9.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual, 2nd ed. New York: Cold Spring Harbor Laboratory; 1989. [Google Scholar]

Articles from World Journal of Gastroenterology : WJG are provided here courtesy of Baishideng Publishing Group Inc

RESOURCES